Carriers of the Complex Allele $HFE$ c. [187C>G;340+4T>C] Have Increased Risk of Iron Overload in São Miguel Island Population (Azores, Portugal)

Claudia C. Branco1,2,3☯, Cidália T. Gomes1☯, Laura De Fez1☯, Sara Bulhões1, Maria José Brilhante1, Tânia Pereirinha1, Rita Cabral1, Ana Catarina Rego4, Cristina Fraga5, António G. Miguel6, Gracinda Brasil7, Paula Macedo7, Luisa Mota-Vieira1,2,3*

1 Molecular Genetics and Pathology Unit, Hospital of Divino Espirito Santo of Ponta Delgada, EPE, São Miguel Island, Azores, Portugal, 2 Instituto Gulbenkian de Ciência, Oeiras, Portugal, 3 BioISI – Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisbon, Lisboa, Portugal, 4 Gastroenterology Department, Hospital of Divino Espirito Santo of Ponta Delgada, EPE, São Miguel Island, Azores, Portugal, 5 Hematology Department, Hospital of Divino Espirito Santo of Ponta Delgada, EPE, São Miguel Island, Azores, Portugal, 6 Pneumology Department, Hospital of Divino Espirito Santo of Ponta Delgada, EPE, São Miguel Island, Azores, Portugal, 7 Internal Medicine Department, Hospital of Divino Espirito Santo of Ponta Delgada, EPE, São Miguel Island, Azores, Portugal

☯ These authors contributed equally to this work.
* Luisa.MQ.Vieira@azores.gov.pt

Abstract

Iron overload is associated with acquired and genetic conditions, the most common being hereditary hemochromatosis (HH) type-I, caused by $HFE$ mutations. Here, we conducted a hospital-based case-control study of 41 patients from the São Miguel Island (Azores, Portugal), six belonging to a family with HH type-I pseudodominant inheritance, and 35 unrelated individuals fulfilling the biochemical criteria of iron overload compatible with HH type-I. For this purpose, we analyzed the most common $HFE$ mutations – c.845G>A [p.Cys282Tyr], c.187C>G [p.His63Asp], and c.193A>T [p.Ser65Cys]. Results revealed that the family’s HH pseudodominant pattern is due to consanguineous marriage of $HFE$-c.845G>A carriers, and to marriage with a genetically unrelated spouse that is -c.187G carrier. Regarding unrelated patients, six were homozygous for c.845A, and three were c.845A/c.187G compound heterozygous. We then performed sequencing of $HFE$ exons 2, 4, 5 and their intron-flanking regions. No other mutations were observed, but we identified the -c.340+4C [IVS2+4C] splice variant in 26 (74.3%) patients. Functionally, the c.340+4C may generate alternative splicing by $HFE$ exon 2 skipping and consequently, a protein missing the α1-domain essential for $HFE$/transferrin receptor-1 interactions. Finally, we investigated $HFE$ mutations configuration with iron overload by determining haplotypes and genotypic profiles. Results evidenced that carriers of $HFE$-c.187G allele also carry -c.340+4C, suggesting cis configuration. This data is corroborated by the association analysis where carriers of the complex allele $HFE$-c.[187C>G;340+4T>C] have an increased iron overload risk (RR = 2.08, 95% CI = 1.40–2.94, p<0.001). Therefore, homozygous for this complex allele are at
risk of having iron overload because they will produce two altered proteins—the p.63Asp [c.187G], and the protein lacking 88 amino acids encoded by exon 2. In summary, we provide evidence that the complex allele HFE-c.[187C>G;340+4T>C] has a role, as genetic predisposition factor, on iron overload in the São Miguel population. Independent replication studies in other populations are needed to confirm this association.

Introduction

Iron overload in humans is associated with a variety of acquired and genetic conditions, the most common being the hereditary hemochromatosis type-I (HH, OMIM #235200), an autosomal recessive disorder caused by mutations in the HFE (High Iron Fe, OMIM *613609) gene [1]. HFE encodes an HLA-A class 1-like protein and is located on 6p21.3, 4 megabases (Mb) telomeric to the human leukocyte antigen region (HLA).

Two HFE mutations-- c.845G>A [p.Cys282Tyr] and c.187C>G [p.His63Asp]—were originally described in association with HH [2]. The majority (60% to 90%) of clinically diagnosed probands were homozygous for c.845A [p.282Tyr], and 5% were c.845A/c.187G compound heterozygous. In terms of molecular pathology, the c.845A is the most severe mutation. Its frequency decreases from the north to the south of Europe and is very low in non-European derived populations, such as Asians [3], Africans [4] and Ashkenazi Jewish [5]. The second originally described mutation-- c.187G [p.63Asp]—is found as a highly frequent polymorphism in general populations [2]. Nonetheless, it was observed at an increased frequency in HH patients’ chromosomes that do not carry the c.845A mutation [2,6], suggesting a possible role as a modifier of iron overload. A third sequence variant in the HFE gene -- c.193A>T [p. Ser65Cys] – was increased in some HH patients' groups in comparison to healthy controls [7,8]. Despite the fact that individuals with the c.845A/c.193T genotype may have an increased risk to express a milder form of HH, the penetrance of this genotype is low and other genetic and environmental factors may influence the expression of iron overloading [9]. Other HFE single nucleotide polymorphisms and rare variants have been implicated in hemochromatosis [10,11], including intronic splicing mutations, such as c.340+4T>C [IVS2+4T>C] [12] and c.1008+1G>A [IVS5+1G>A] [13]. For example, Floreani and colleagues [11] showed that two cis-variants-- c.193T and c.340+4C—generate alternative splicing by HFE exon 2 skipping. The corresponding protein misses the α1-domain, which is essential for the interaction of HFE with TfR1 (Transferrin Receptor-1) [14].

Despite recent advances, a better understanding of the molecular basis of iron overload is needed in order to improve patients’ disease outcome through early diagnosis and treatment. Here, we conducted a hospital-based case-control study of individuals living in the Azorean island of São Miguel in order to genetically characterise a family with pseudodominant inheritance of hereditary hemochromatosis (HH) type-I, and an additional group of unrelated patients that fulfilled the biochemical criteria of iron overload compatible with HH type-I. To that end, we genotyped four HFE mutations/variants-- c.845G>A [p.Cys282Tyr], c.187C>G [p.His63Asp], c.193A>T [p.Ser65Cys], and c.340+4T>C [IVS2+4T>C]—and performed an association analysis of HFE haplotypes and genotypic profiles with this condition. Since several HLA haplotypes have been associated with HFE-c.845A and -c.187G, we also studied the HLA-A and -B group alleles and haplotypes linked to these mutations in the São Miguel Island.
Material and Methods

Ethics statement

The present investigation follows the international ethical guidelines and was approved by the Health Ethics Committee of the Hospital of Divino Espírito Santo of Ponta Delgada, EPE (HDES). The study design includes, from all participants, written informed consent, confidentiality, and an abandonment option in the case of expressed will.

The general population consists of 469 DNA samples of unrelated healthy blood donors from São Miguel Island selected from the anonymized Azorean DNA bank, located at HDES. This DNA bank was established after approval by the Health Ethics Committee and follows, as well, the international ethical guidelines for sample collection, processing, and storage.

São Miguel Island population (Azores): Bio-demographic data and general population sampling

São Miguel is the largest (747 Km², measuring 64 km from east to west and 8 to 15 km wide) and the most populated Azorean island (137,699 inhabitants; 55.9% total Azores population; Portugal Census, 2011). This island was uninhabited when discovered in 1427. Nowadays, the island is divided in six municipalities: Ponta Delgada (PDL, 68,809 inhabitants, 49.9%), Ribeira Grande (RG, 32,112 inhabitants, 23.3%), Lagoa (LAG, 14,442 inhabitants, 10.5%), Vila Franca do Campo (VFC, 11,229 inhabitants, 8.1%), Povoação (POV, 6327 inhabitants, 4.6%) and Nordeste (NOR, 4937 inhabitants; 3.6%). Around half of the São Miguel population lives in small rural localities. The rural area is characterized by agriculture and cattle-breeding economy, and its inhabitants show great similarity in lifestyle, as well as in eating habits. Regarding iron metabolism, the literature review did not reveal any previous study on iron overload in this population.

The general population cohort is composed of 469 DNA samples of unrelated healthy blood donors from São Miguel Island (Azores, Portugal). This sample was geographically representative of the six municipalities of the island: PDL (n = 176), VFC (n = 87), RG (n = 76), POV (n = 51), NOR (n = 41) and LAG (n = 38). Ninety-seven percent of the subjects studied have parents born in the same locality.

Iron overload patients

A total of 41 patients (Table 1) were clinically characterized by six physicians (Internal Medicine, Gastroenterology, Hematology, and Pneumology departments) at the HDES. Six patients belong to one family studied in the context of a family screening of hemochromatosis. They live in a small rural locality with less than 600 inhabitants. The remaining 35 unrelated patients were referred for HFE genotyping, since they fulfilled the biochemical criteria of iron overload compatible with the classical form of hereditary hemochromatosis (type-I)– 1. serum ferritin > 400 ng/mL (males) or > 300 ng/mL (females), and/or 2. transferrin saturation (TS) > 50% (males) or > 45% (females), and/or 3. serum iron > 160 μg/dL (males) or > 145 μg/dL (females). Patients with evidence of secondary iron overload, namely exogenous iron intake, hepatitis B or C infection, and daily alcohol consumption higher than 60g, were excluded from the study. All patients and their parents were born in São Miguel Island, being the majority with both parents born in the same municipality (66%; Table 1). Blood samples were collected by venipuncture into dry and EDTA-K₃ tubes for biochemical and mutation analysis, respectively. Genomic DNA was extracted using the PUREGENE® DNA Purification (Gentra systems Inc.) or Citogene® DNA Purification (Citomed) kits. Serum transferrin, iron, and transaminases (aspartate transaminase, AST, and alanine transaminase, ALT) were measured.
Table 1. Demographic, clinical, biochemical and genetic data from the 41 iron overload patients from São Miguel Island.

| ID | Sex | Age (years) | Family patients affected with hereditary hemochromatosis (pseudodominant transmission) | HFE genotype | HLA A B | MSA | Clinical manifestations | Demographic data | Biochemical tests | MSA | HFE genotype | MSA | HFE genotype |
|----|-----|-------------|------------------------------------------------------------------------------------------|--------------|--------|-----|-----------------------|------------------|-----------------|-----|--------------|-----|--------------|
| 1  | F   | 23          | AA                                                                                       | 01, 02       | 212    | ND  | No                    | Male             | Serum iron (μg/dL) | 1000| 80           | 212| 55           |
| 2  | M   | 51          | AA                                                                                       | 02, 31       | 49     | 14  | No                    | Male             | Serum iron (μg/dL) | 1000| 45           | 14  | 44           |
| 3  | M   | 30          | AA                                                                                       | 01, 02       | 68     | 16  | No                    | Male             | Serum iron (μg/dL) | 1000| 157          | 16  | 64           |
| 4  | M   | 16          | AA                                                                                       | 01, 02       | 29     | 12  | No                    | Male             | Serum iron (μg/dL) | 1000| 44           | 12  | 49           |
| 5  | M   | 20          | AA                                                                                       | 01, 02       | 13     | 63  | No                    | Male             | Serum iron (μg/dL) | 1000| 28           | 63  | 43           |
| 6  | M   | 20          | AA                                                                                       | 01, 02       | 20     | 64  | No                    | Male             | Serum iron (μg/dL) | 1000| 23           | 64  | 35           |
| 7  | F   | 23          | AA                                                                                       | 01, 02       | 52     | 20  | No                    | Female           | Serum iron (μg/dL) | 1000| 35           | 20  | 43           |
| 8  | F   | 22          | AA                                                                                       | 01, 02       | 33     | 42  | No                    | Female           | Serum iron (μg/dL) | 1000| 44           | 42  | 35           |
| 9  | M   | 20          | AA                                                                                       | 01, 02       | 31     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 10 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 21           | 44  | 35           |
| 11 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 12 | F   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Female           | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 13 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 14 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 15 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 16 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 17 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 18 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 19 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 20 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 21 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 22 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 23 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 24 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 25 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 26 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 27 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 28 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 29 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 30 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 31 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |
| 32 | M   | 20          | AA                                                                                       | 01, 02       | 24     | 44  | No                    | Male             | Serum iron (μg/dL) | 1000| 24           | 44  | 35           |

| wt, wild-type; ND, not determined; TS, transferrin saturation; AST, aspartate transaminase; ALT, alanine transaminase; F, female; M, male; †, observable values non-concordant with the expected ones; a, the parents were born in the same locality; b, values below the expected since the patient menstruates. | doi:10.1371/journal.pone.0140228.t001

PLOS ONE | DOI:10.1371/journal.pone.0140228 October 26, 2015 4/17
on a Roche/Hitachi 912 by an immunoturbidimetric, colorimetric assays, and UV test, respectively. Transferrin saturation was calculated according to the formula \((\text{Fe/ (transferrin} \times 1.4)) \times 100\). Serum ferritin was determined using the AxSYM Ferritin Assay (Abbott Laboratories).

**HFE mutation analysis**

HFE mutation analysis – c.187C>G [p.His63Asp], c.193A>T [p.Ser65Cys], c.340+4T>C [IVS2+4T>C], and c.845G>A [p.Cys282Tyr] – was performed by several techniques. The detection of c.187C>G, c.193A>T, and c.845G>A was carried out by two methods: i) polymerase chain reaction followed by specific restriction enzyme (PCR-RFLP) [15] for 35 patients and 469 general population individuals, or ii) real-time PCR using TaqMan® genotyping assays for 6 patients.

In RFLP analysis, PCR products from exons 2 (208 base pairs, bp, for c.187C>G and c.193A>T) and 4 (30 bp for c.845G>A) were digested for 2 hours at 37°C with Rsal for c.845G>A, Mbol for c.187C>G and HinfI for c.193A>T (New England Biolabs). The digestion products were size resolved by electrophoresis on 4% agarose gel and visualized by SYBR® Green I nucleic acid gel stain (Molecular Probes). For the c.845G>A, the Rsal produced two fragments of 250 and 140 bp in the wild type DNA and three fragments of 250, 111 and 29 bp in the mutated DNA. In the case of wild type DNA for c.187C>G, the Mbol generated two fragments of 138 and 70 bp, whereas for HinfI the two fragments have 147 and 61 bp; both c.187C>G and c.193A>T mutated DNA were not cut.

In the real-time PCR analysis, we genotyped the c.187C>G (rs1799945) and c.845G>A (rs1800562) mutations by TaqMan® Pre-Designed SNP Genotyping Assays on an ABI 7500 Fast Real-Time PCR System, according to the manufacturer’s instructions (Applied Biosystems). For the c.193A>T mutation, an in-house assay was developed [16] as follows: a 25 μl reaction consisting of TaqMan® genotyping PCR master mix, 32 ng of genomic DNA, 300 nM of each primers 5′-TTGGGCTACGTGGATGACC-3′ and 5′-TCTGGCTTGAAATTCTACTGGAAA-3′ and 150 nM of each TaqMan® MGB probes, 5′-VIC-ACGGCGACACTCANFQ-3′ (mutated) and 5′-FAM-CGGCGACTCTCANFQ-3′ (wild-type). The PCR conditions were as follows: 1 min at 60°C, 10 min at 95°C, followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C.

Considering patients’ clinical manifestations and their HFE status (the majority of patients are not c.845A homozygous), we also performed direct sequencing of HFE exons 2, 4 and 5, including exon-intron boundaries. For this, we used the primers described above for RFLP analysis; however, for exon 5 the following primers were used: 5′-GATGAGAGCCAGGAGCTGAG-3′ and 5′-CCCTGGGGCAGAGGTACT-3′. The exon 2 and its intron-flanking sequences analysis allows for the identification of the c.340+4T>C [IVS2+4T>C] splice site variation, which has been reported as associated with iron overload [11], whereas sequencing of exon 5 and its intron-flanking regions allows for the evaluation of the splice site mutation c.1008+1G>A [IVS5+1G>A] [13]. Each 20 μl PCR amplification reaction contained 100 ng of genomic DNA, 10 μM primers, 200 μM dNTPs (Promega), 25 nM MgCl2 (Qiagen), 1x Q-Solution (Qiagen), 1x buffer (Qiagen), 5 U of HotStart Taq (Qiagen), and sterile water. The PCR started with an enzyme activation step at 95°C for 15 min, then 40 cycles at 94°C for 30s, 56.5°C for 30s and 72°C for 1 min, followed by a final extension step at 72°C for 10 min. Amplification products were purified using the QIAquick PCR Purification kit (Qiagen), according to the manufacturer’s instructions. Purified products were sequenced, using the same primers of the PCR amplification, with the BigDye Terminator v1.1 cycle sequencing kit (Applied Biosystems) under the following conditions: 1 μl ready reaction mix, 5 μl BigDye sequencing buffer, 3.2 pmol of forward or reverse primer, 7 ng DNA, and sterile water to a final reaction volume of 20 μl. Cycle sequencing was performed using a initial denaturation step at 96°C for 1 min followed by 25
cycles at 96°C for 10s, 50°C for 5s, and 60°C for 4 min in a GeneAmp® PCR System 2700 (Applied Biosystems). The sequencing products were purified with a BigDye XTerminator® Purification kit, and separated by capillary electrophoresis in an automated sequencer (ABI 3130 Genetic Analyzer, Applied Biosystems) with a 36 cm length capillary and POP-7™ polymer, according to the manufacturer’s instructions. Data were analyzed with the Sequencing Analysis software version 5.3.1 (Applied Biosystems). The alignment and edition of sequences were carried out using the Bioedit™ software version 7.0.0.

Sequencing results revealed the presence, in some patients, of the splice site variation c.340 +4T>C (rs2071303). Consequently, this variant was genotyped in the general population (469 individuals) by TaqMan® Pre-Designed SNP Genotyping Assays (Applied Biosystems) on an ABI 7500 Fast Real-Time PCR System, according to manufacturer’s instructions.

**HLA genotyping**

**HLA–A and–B** genotyping was performed in the 41 patients by PCR amplification with sequence-specific primers (PCR-SSP), according to the manufacturers’ instructions (Olerup SSP®, GenoVision Inc.). After electrophoresis on a 4% agarose gel stained with SYBR® Green, the PCR products were visualized, followed by **HLA** group allele identification using the Helberg-SCORE™—Sequence Compilation and Rearrangement Evaluation, for research only—software (Olerup SSP AB). This methodology only allows a low resolution genotyping. Consequently, **HLA** was characterized in a group level resolution, and the specific alleles present in each group were not discriminated.

**Statistical analysis**

Allele and genotype frequencies were estimated for the **HFE-c.187C>G, -c.193A>T, -c.340 +4T>C, and -c.845G>A** mutations in the general population (n = 469). Hardy-Weinberg equilibrium (HWE) for the general population was determined by the Arlequin software v.3.5.1.2. No departure from HWE was observed. Then, contingency tables were constructed to calculate the statistical differences between the allele frequencies in the six municipalities of the island. Fisher’s exact test was used instead of a chi-square test, since the last may be inapplicable for very small expected frequencies (number of subjects in a cell should be 5 or more). Data analysis was carried out using the statistical package SPSS software, version 10.0 (SPSS, Inc.). The results were considered statistically significant when the p values were less than 0.05.

The **HLA–A and–B** group alleles’ frequencies were calculated by direct counting. The **HFE-c.845A-HLA-A-B** haplotypes were directly obtained by segregation analysis through five consecutive generations in the family affected with pseudodominant inheritance of HH, and by–A and–B group alleles’ homozygosity in two unrelated patients (patients 3 and 5). The same strategy was applied to determine the **HFE-c.187G-HLA-A-B** (patient 14). For a random subset (93 individuals) of the general population, the **HLA** haplotypes were estimated with the expectation-maximization (EM) algorithm provided in the Arlequin package, as previously described [17].

Association analysis of iron overload with **HFE** and **HLA** haplotypes, as well as with **HFE** genotypic profiles, was performed by calculating relative risks (RRs) with 95% confidence intervals (CI) using the 2-way Contingency Table Analysis webpage ([http://statpages.org/ctab2x2.html](http://statpages.org/ctab2x2.html)).
Results

Study of a family affected with pseudodominant inheritance of hereditary hemochromatosis type-I

The study of hereditary hemochromatosis in São Miguel Island began in 1988 by the identification of two brothers—the proband (patient IV.7) and one sibling (patient IV.8)—with a classical clinical picture of HH and one paternal uncle affected with a minor form of the disease (III.3, Fig 1). In 2000, after the introduction of the HFE gene testing, this family, which is from a small village with less than 600 inhabitants, was reinvestigated in order to understand the HH segregation and to offer a better follow up of their relatives [18]. Their family pedigree, which spans five generations, is shown on Fig 1. The HH phenotype was identified in nine family members, from II to V consecutive generations: three patients (II.2, III.2 and III.7) by clinical and family history, and six patients (III.3, IV.7, IV.8, IV.12, V.10 and V.11) by clinical, biochemical, and HFE genotyping. A summary of the demographic, clinical, biochemical and genetic data of these patients is shown in Table 1. The proband (42y, IV.7) and one brother (40y, IV.8) presented the classical clinical picture of hereditary hemochromatosis type-I, including a transferrin saturation higher than 80% and a serum ferritin higher than 1000 ng/mL. The paternal uncle (74y, III.3) had only a slightly elevated serum ferritin. They were all homozygous for the mutated allele HFE-c.845A [p.282Tyr]. Following the characterization of these first three patients, a biochemical and genetic screening was given to 11 additional family members. First, we investigated three sisters (IV.5, IV.10 and IV.12) of the two affected brothers and the daughter (IV.2) of the affected paternal uncle. The mutation analysis revealed that one clinically asymptomatic sister (37y, IV.12) was HFE-c.845A homozygous, being the other three heterozygotes for this mutation (c.845GA). We performed a clinical evaluation and genetic testing to the other five family members living in the São Miguel Island, namely the proband spouse (IV.6), three husbands of proband sisters (IV.4, IV.9 and IV.11), and the husband of one first-cousin (IV.3). The HFE analysis showed that the spouse of the proband (IV.6), which is non-related, is heterozygous for the c.187G [p.63Asp] mutation. Therefore, the molecular screening was also offered to their three children, aged 20 (V.10, female), 18 (V.11, male) and 15 (V.12, male) years-old, since they were suspected to be HFE-c.845A/c.187G.
compound heterozygous. This hypothesis was confirmed in the daughter (V.10) and in one son (V.11). Both were clinically asymptomatic, but presented high transferrin saturation levels.

**HFE mutation analysis of unrelated patients with biochemical evidence of iron overload**

*HFE* genotyping for the three most common mutations associated with iron overload was performed in 35 unrelated patients from the São Miguel Island (Azores) who were referred by their physicians due to suspicion of the classical form of hereditary hemochromatosis (type-I), based on biochemical criteria of iron overload (see M&M). A summary of the demographic, clinical, biochemical, and genetic data of these patients is also presented in Table 1. Six of the 35 patients (17%) were homozygous for *HFE-c.845A* [p.282Tyr], and three were *c.845A/c.187G* compound heterozygous. In these nine patients, the predominant clinical manifestations were skin pigmentation and arthropathy; three patients presented liver cirrhosis, one in association with classical hemochromatosis and bronze diabetes (patient 5 in Table 1). Although the highest TS values were found in patients homozygous for *c.845A* mutation, there was not, in general, a clear-cut correlation between patients’ genotype and biochemical data.

Sequencing of *HFE* exons 2, 4 and 5 and their intron-flanking regions in all patients (6 familiar and 35 unrelated) did not reveal any other mutation, but allowed the identification of the *c.340+4C* [IVS2+4C] splice site variant in 26 patients (Table 1), either in a heterozygous (19) or in a homozygous state (7). In three patients (#32–34; Table 1), this variant was the only *HFE* mutation present. Overall, considering the four *HFE* mutations—*c.187C>G* [p.His63Asp], *c.193A>T* [p.Ser65Cys], *c.340+4T>C* [IVS2+4T>C], and *c.845G>A* [p.Cys282Tyr]—around 60% of unrelated patients (21 out of 35) have at least two mutations, found in-*cis* or in-*trans* position, which may explain the iron overload. In seven of these 21 patients (33.3%), the *HFE-c.187G* and -*c.340+4C* variants are in-*cis* configuration. This result is corroborated by the *HFE* haplotypes and genotypic profiles analysis, where individuals carrying the *c.187G* allele also carry -*c.340+4C* (H2, GP2-5, and GP3, Tables 2 and 3), and by the linkage disequilibrium (D’ = 0.826) between the two variants. Finally, carriers of both variants have increased risk of developing iron overload (RR = 2.08 95% CI = 1.40–2.94, p < 0.001; Table 2 HFE-H2), despite neither, by themselves, are associated with this condition (c.187G RR = 1.14, 95% CI 0.72–1.72, p = 0.546; and -*c.340+4C* RR = 0.28, 95% CI 0.10–0.66, p = 0.001; Table 2 HFE-H4).

**Association analysis of HFE haplotypes and genotypic profiles with iron overload**

In order to assess the association of *HFE* haplotypes (H) and genotypic profiles (GP) with iron overload we calculated relative risk (RR) by comparing the 41 patients against the general population. The haplotypes RR results revealed that H1CATA (RR = 10.40, 95% CI = 6.51–16.36, p < 0.001) and H2GACC (RR = 2.08, 95% CI = 1.40–2.94, p < 0.001) confer susceptibility to iron overload (Table 2). On the other hand, a protective effect (p < 0.05) was observed for H3 (wild-type) carriers. *HFE* genotypic profile data demonstrated a significant positive association of profiles GP1CCAA TTAA (RR = 114.39, 95% CI = 16.04–2386.15, p < 0.001), GP2CG AA TC GA (RR = 19.07, 95% CI = 4.10–98.88, p < 0.001) and GP3CG AT CC GG (RR = 11.44, 95% CI = 1.17–112.26, p = 0.002) with iron overload (Table 3), whereas GP10CC AA TT GG showed a protective effect, as expected.
Genetic background of \textit{HFE}-c.845A and -c.187G mutations and association analysis of \textit{HLA} haplotypes with iron overload

In order to determine the genetic background of \textit{HFE}-c.845A [p.282Tyr] and -c.187G [p.63Asp] mutations, we assessed the \textit{HLA}-A–B haplotypes in patients homozygous for -c.845A and -c.187G. A total of six \textit{HLA} haplotypes (H1 – H6; Table 2) associated with \textit{HFE}-c.845A mutation were identified: A/C301-B/C335 (H1), A/C302-B/C355 (H2), A/C302-B/C344 (H3), A/C324-B/C315 (H4), A/C303-B/C327 (H5), and A/C303-B/C350 (H6). Of these, three—H1, H2, and H3—were directly inferred by family segregation analysis (Fig 1). The remaining three haplotypes were directly inferred from two \textit{HFE}-c.845A homozygous unrelated patients. These patients also presented homozygosity for \textit{HLA} group alleles: patient 3 for A/C303, providing the H5 and H6 haplotypes, and patient 5 for both A/C324 and B/C315 group alleles, generating the H4. For the latter patient, the extended \textit{HLA} haplotype also revealed homozygosity for group alleles C/C303, DRB1*11, DQA1*05 and DQB1*03. Regarding \textit{HFE}-c.187G [p.63Asp] homozygous patients, two \textit{HLA}-A-B haplotypes were directly inferred: patient 14 for B/C349 – A/C303-B/C349 (H7) and A/C332-B/C349 (H8).

General population’s \textit{HLA}-A–B haplotypes were determined, by indirect inference, without \textit{HFE}-c.845A and -c.187G carrier information. In this subset, a total of 84 haplotypes were identified, being A/C301-B/C308 (0.086), A/C302-B/C344 (0.066), and A/C324-B/C308 (0.043) the most frequent (S1 Table). The patients’ direct haplotype inference revealed that, with the exception of A/C303-B/C350 (H6) and A/C303-B/C349 (H7), all other patients’ haplotypes were present in the general population (Table 2).

To investigate the association of \textit{HLA} group alleles and haplotypes with iron overload, we calculated relative risk by comparing the 41 patients against the general population. The data demonstrated a significant positive association of B/C35 (RR = 2.65, 95% CI = 1.20–5.87, Table 2).

Table 2. \textit{HFE} and \textit{HLA} haplotype frequency and association analysis with iron overload. \textit{HFE} haplotypes were indirectly inferred by Arlequin, whereas \textit{HLA} haplotypes were directly inferred by homozygosity.

| Locus | ID | Frequency | Association analysis |
|-------|----|-----------|----------------------|
| \textit{HFE} | c.187C>G | c.193A>T | c.340+4T>C | c.845G>A |
| H1 | C | A | T | A | 0.326 | 0.035 | 10.40 | 6.51–16.36 | <0.001 |
| H2 | G | A | C | G | 0.315 | 0.152 | 2.08 | 1.40–2.94 | <0.001 |
| H3 | C | T | C | G | 0.022 | 0.016 | 1.53 | 0.24–6.73 | 0.569 |
| H4 | C | A | C | G | 0.098 | 0.217 | 0.28 | 0.10–0.66 | 0.001 |
| H5 | C | A | T | G | 0.239 | 0.509 | 0.46 | 0.29–0.67 | <0.001 |
| H6 | C | A | T | G | 0.239 | 0.509 | 0.46 | 0.29–0.67 | <0.001 |
| H7 | C | A | T | G | 0.239 | 0.509 | 0.46 | 0.29–0.67 | <0.001 |
| H8 | C | A | T | G | 0.239 | 0.509 | 0.46 | 0.29–0.67 | <0.001 |
| \textit{HLA} | A | B |
| H1 | 01 | 35 | 0.073 | 0.005 | 13.61 | 1.68–299.82 | <0.001 |
| H2 | 02 | 55 | 0.073 | 0.005 | 13.61 | 1.68–299.82 | <0.001 |
| H3 | 02 | 44 | 0.061 | 0.066 | 0.95 | 0.30–2.78 | 0.913 |
| H4 | 24 | 15 | 0.049 | 0.005 | 9.07 | 0.98–212.98 | 0.016 |
| H5 | 03 | 27 | 0.024 | 0.005 | 4.54 | 0.33–126.13 | 0.173 |
| H6 | 03 | 50 | 0.012 | <0.001 | 0.76 | 0.03–8.00 | 0.807 |
| H7 | 03 | 49 | 0.037 | <0.001 | 0.76 | 0.03–8.00 | 0.807 |
| H8 | 32 | 49 | 0.012 | 0.016 | 0.76 | 0.03–8.00 | 0.807 |

\^H1-H6 and H7-H8 were associated with \textit{HFE}-c.845A and \textit{HFE}-c.187G, respectively.

doi:10.1371/journal.pone.0140228.t002

\textit{HFE} c.[187C>G;340+4T>C] Increases Risk of Iron Overload
p = 0.007) and B’55 group alleles (RR = 6.80, 95% CI = 1.28–48.45, p = 0.006) with iron overload; but, when we removed HFE-c.845A [p.282Tyr] carriers, which include homozygous and heterozygous individuals, this association became statistically non-significant. Regarding the haplotype analysis, a total of 47 different haplotypes were indirectly inferred in the patient sample; however, we only report results for patients’ directly inferred HLA-A–B haplotypes (Table 2). The data showed a positive association for A/C301-B/C335 (H1: RR = 13.61, 95% CI = 1.68–299.82, p = 0.001) and A/C302-B/C355 (H2: RR = 13.61, 95% CI = 1.68–299.82, p = 0.001). Once more, when HFE-c.845A [p.282Tyr] carriers were removed, the statistical significance was lost. These results validate the association of these two HLA haplotypes with the HFE-c.845A mutation. The remaining four HLA haplotypes (H3–6) did not present a significant risk. Considering HLA haplotypes associated with HFE-c.187G [p.63Asp], results did not demonstrate an increased risk for iron overload.

The HFE mutations in São Miguel population and its geographical distribution

Since the São Miguel population lives on an island, we studied the prevalence of the four HFE mutations. Table 4 summarizes the results concerning allele and genotype frequencies for the HFE mutations in 41 patients and 469 general population individuals. The c.845A [p.282Tyr] mutation frequency in São Miguel population was 0.05, predicting one in 400 individuals could be c.845A homozygous (Table 5) and one in 10 individuals should be heterozygous. The c.187G [p.63Asp] had the second highest allelic frequency (0.204), indicating a c.187G homozygosity and heterozygosity frequencies of one in 24 and one in three individuals of the general population, respectively. Taken together, it is expected 2.04% of c.845A/c.187G compound heterozygous (one out of 49, Table 5) in the São Miguel Island population. The allele frequency of the third mutation studied – c.193T [p.65Cys]– was the lowest observed (0.02), which predicts a heterozygote frequency of one out of 25 subjects in the whole population. Finally, the c.340+4C [IVS2+4C] splice site variation showed the highest allelic frequency (0.401), representing a heterozygote frequency of one in two individuals of the general population. Considering genotype frequencies of the 469 subjects, one (0.002) was c.845A homozygous, 26 (0.055) were c.187G homozygous, and five (0.011) were compound heterozygous for c.845A/c.187G (Table 4).
c.193T mutation was found in 19 subjects: two (0.004) were compound heterozygous for c.845A, and five (0.011) were compound heterozygous for c.187G (Table 4).

Table 4. Allele and genotype frequencies of HFE mutations in patients with iron overload and in the general population from São Miguel Island.

| HFE mutation | Allele | Frequency | Genotype | Frequency |
|--------------|--------|-----------|----------|-----------|
| c.845G>A     | ID     | Iron overload patients | General population | ID | Iron overload patients | General population |
| A            | 0.366  | 0.050     | AA       | 0.244     | 0.002     |
| G            | 0.634  | 0.950     | GA       | 0.244     | 0.096     |
| c.187C>G     | G      | 0.317     | GG       | 0.098     | 0.055     |
| C            | 0.683  | 0.796     | CG       | 0.439     | 0.296     |
| c.193A>T     | T      | 0.024     | TT       | 0         | 0         |
| A            | 0.976  | 0.980     | AT       | 0.049     | 0.041     |
| c.340+4T>C   | C      | 0.402     | CC       | 0.171     | 0.177     |
| T            | 0.598  | 0.599     | TC       | 0.463     | 0.448     |
|               |        |           | TT       | 0.366     | 0.375     |

Compound heterozygotes

| HFE mutation | Allele | Frequency |
|--------------|--------|-----------|
| c.845A/c.187G|        | 0.061     |
| c.845A/c.193T|        | 0         |
| c.187G/c.193T|        | 0.024     |

Note. None of the 35 patients were carriers of the c.1008+1G>A [IVS5+1G>A] variant, therefore we do not present data for patients and general population.

c.193T mutation was found in 19 subjects: two (0.004) were compound heterozygous for c.845A, and five (0.011) were compound heterozygous for c.187G (Table 4).

In order to assess the relationship between the four HFE mutations (c.845A, c.187G, c.193T, and c.340+4C) and their geographical distribution in the São Miguel Island, we compared allele frequencies between the six municipalities (Fig 2). For c.845A, the highest value is found in Nordeste (9.8%) followed by Povoação (5.9%), and the lowest in Lagoa (2.6%). We observed a significant difference (p = 0.048) between Nordeste and the other five municipalities (PDL, RG, LAG, VFC, and POV), indicating a relatively non-uniform island distribution for the c.845A mutation. On the other hand, the other three variants—c.187G, c.193T, and c.340+4C—showed a uniform pattern with no significant differences among municipalities.

Table 5. Expected number of individuals homozygous or compound-heterozygous for the HFE- c.845G>A [p.Cys282Tyr] or -c.187C>G [p.His63Asp] in Azores, Madeira, and mainland Portugal.

| Portugal         | Expected HFE genotype frequencies |
|------------------|----------------------------------|
|                  | c.845GA/c.845A | c.845A/c.187G |
| Azores           |                 |               |
| São Miguel Island| 1 in 400        | 1 in 49       | Present study |
| Terceira Island  | 1 in 2347       | 1 in 132      | 27            |
| Madeira Island   | 1 in 84.333     | 1 in 154      | 34            |
| mainland         |                   |               |
| North and Centre | 1 in 368        | 1 in 49       | 28            |
| South            | 1 in 2268       | 1 in 143      | 28            |

doi:10.1371/journal.pone.0140228.t005
Considering that the São Miguel population has an admixed genetic background composed mainly of Europeans and less by Jews and Africans [19–25], we compared the HFE mutations frequencies with other populations. The analysis revealed that islanders have a c.845A [p.282Tyr] frequency similar to that found in several countries in northern Europe (≈5.7%) [26], but significantly different from the reported frequencies for the Azorean island of Terceira (2.1%) [27]. Regarding c.187G [p.63Asp], the highest frequency observed in Portugal has been detected in the Madeira archipelago (20.5%), followed by São Miguel Island (20.4%), north and center mainland (19.7%) [28] and Terceira Island (18.3%) [27]. The frequencies detected for these two HFE mutations (c.845A and c.187G) in São Miguel are significantly higher than those found in Jewish (1.3 and 9.7%) [5] and African (0.9% and 13.2%) [4] populations. As expected, the c.340+4C variation presented similar allelic frequency with phase III CEU HapMap population (34.1%).

Discussion
Iron overload disorders represent a heterogeneous group of conditions resulting from inherited and acquired means. Despite recent advances, a better understanding of the molecular basis of iron overload is needed in order to improve patient’s disease outcome through early diagnosis and treatment. Here, we carried out, for the first time, a clinical evaluation of 41 iron overload patients from the Azorean island of São Miguel (Portugal), which were referred for HFE genotyping. Of these, six patients belong to a family with a pseudodominant inheritance of HH. Furthermore, we assessed the frequency of four HFE mutations—c.187C>G [p.His63Asp], c.193A>T [p.Ser65Cys], c.340+4T>C [IVS2+4T>C] and c.845G>A [p.Cys282Tyr]—in 469 healthy individuals living on the same island. Association analysis of HFE haplotypes and genotypic profiles with iron overload were also evaluated. Finally, we studied the HLA-A and -B group alleles and haplotypes linked with the HFE-c.845A and HFE-c.187G mutations.

In the present research, the patients’ clinical evaluation demonstrate that around 43.9% (18 out 41) present serum ferritin higher than 1000 ng/mL, and 29.3% (12 out 41) show HH’s clinical manifestations, the most frequent being hyperpigmentation and hepatic cirrhosis. Moreover, there is a higher frequency of HFE-c.845A homozygous individuals in the patient cohort (24.4%) compared to the general population (0.2%). The majority of patients presenting an iron overload did not fulfill the criteria of HH, suggesting that additional environmental or genetic factors could contribute to iron overload. Sequencing of HFE exons 2, 4 and 5, and intron-flanking regions did not reveal any other mutation, but allowed the identification of c.340+4C [IVS2+4C] splice site variant in 63.4% patients (26 out of 41, Table 1). This variant alone does not explain iron overload (RR = 0.28, 95% CI 0.10–0.66, p = 0.001; Table 2 HFE-H4); however, around 7% (3 out 41) of patients (#32–34, Table 1) were heterozygous for c.340+4T>C and did not show any other HFE mutation. Bioinformatic analysis using the Human Splicing Finder 2.4 (http://www.umd.be/HSF/) [29] revealed that c.340+4T>C has a splicing Δconsensus of +9.71%, a value higher than the expected 7% for a +4 position of 5’ splice site. In fact, this significant impact on splicing is consistent with the biological evidence of exon 2 skipping observed in a patient with histologically-demonstrated iron overload [11]. According to functional studies performed by Martins et al. [14], the protein produced by the c.340+4T>C alternative splicing is retained in the endoplasmic reticulum and do not efficiently reach the plasma membrane with the β2-microglobulin chaperone. A similar situation is observed with the p.282Tyr mutated HFE protein.

Although the pattern of inheritance of HH is usually horizontal, i.e. all patients belong to the same generation, as expected for an autosomal recessive disease, here we describe a vertical (pseudodominant) pattern due to the segregation within the studied family of at least three
HFE mutant alleles in each generation. Common causes for a pseudodominant inheritance pattern are: i) birth of an affected child from an affected individual and a genetically related (consanguineous) reproductive partner, who is an unsuspecting carrier, and ii) high carrier frequency, enhancing the risk that the spouse of a patient is a carrier of a mutation in the same gene [30]. Interestingly, these two conditions are observed in their family pedigree: the proband’s (IV.7) parents are consanguineous and responsible for the transmission of the c.845A allele and the proband’s spouse (IV.6), who is genetically unrelated, carries the second most frequent mutation – c.187G.

The knowledge of mutation origin improves the comprehension of population genetic background and evolution. The analysis of co-segregation of HFE mutations and HLA–A and–B with HH in the family pedigree revealed three non-ancestral HLA–A–B haplotypes associated with the HFE-c.845A mutation: A’01-B’35, A’02-B’44 and A’02-B’55. The first two were also observed in HFE-c.845A homozygous HH patients from the north of Portugal [31]. However, the third haplotype (A’02-B’55) and the A’24-B’15 are, to our knowledge, two new non-ancestral haplotypes associated with this mutation. These two haplotypes reinforce the association of HFE-c.845A mutation with A’02 (linked to, for example, B’07, B’14 and B’35) or A’24 (linked to B’18, B’35 and B’57) group alleles, both observed in northern Portuguese HFE-c.845A homozygous patients [31]. Regarding HFE-c.187G, a previous study [32] reported a significant association of this mutation with A’29 or B’44 group alleles, as well as with A’29-B’44 haplotype in the mainland Portuguese population. The obtained results only show association of the HFE-c.187G mutation alleles with A’03-B’49 or A’32-B’49. Nevertheless, patient 9, who is c.845A/c.187G compound heterozygous, also presents the A’29-B’44 haplotype.

In order to investigate the geographical distribution of the HFE-c.187C>G, -c.193T>C, and -c.845G>A mutations in the São Miguel Island, we compared the allele frequencies between the six municipalities (Fig 2). The data demonstrate a higher frequency of c.845A mutation in Nordeste compared to the other five municipalities (p = 0.048), suggesting a geographic cline from east to west. This observation may lead to theorize the presence of a founder effect; however, the high diversity of HLA haplotypes associated with this mutation does not corroborate this hypothesis. Furthermore, this trend was not observed for the other three HFE variants – c.187G, c.193T and c.340+4C –, which show no significant differences.
among the municipalities. Additionally, we cannot rule out the hypothesis that this result may be due to the small sample size. Nevertheless, the observed pattern validates the importance of carrying out screening studies of recessive mutations in relatively small populations like the Azorean island of São Miguel.

In general, the frequency of c.845A [p.282Tyr] in Europe shows a decreasing north-south cline, with values ranging from 5 to 10% in north Europe, and from 1 to 5% in central and south Europe [33]. The frequency of the c.845A mutation in São Miguel was similar to the one reported in north/central mainland Portugal [28], but significantly higher than in the Azores Terceira Island [27], south mainland Portugal [28], and Madeira Island [34]. This data validates previous results where mainland Portuguese, especially from north/center, were the main contributors to the Azorean settlement. Moreover, these results may be suggestive of different population dynamics between the Azorean islands. Comparison with other populations shows that c.845A frequency is similar to central European countries, reflecting our previous results, where Flemish, French, and Germans also contributed to the settlement of the Azores [21–24].

Concerning the c.187G [p.63Asp] mutation, the highest frequency observed in Portugal has been detected in the Madeira archipelago followed by São Miguel Island. This high frequency is similar to that found in southern Europe. Although the relationship between this mutation and HH is unclear, it constitutes a genetic predisposing factor causing iron overload when present with another genetic (HFE or other gene mutation) or an environmental factor [35]. The results indicated that alone c.187G is not associated with iron overload, but together with c.340+4C [IVS2+4C] splice variant is responsible for an increase in the risk of developing the disease. This result is corroborated by simulation studies, where adding just one patient homozygous for the mutated allele of both variants (GP4 GG AA GC GG, Table 3) had a significantly increase in risk (RR = 3.10, 95% CI 1.03–8.24, $p = 0.016$). We hypothesize that double homozygous individuals will produce two altered HFE proteins—the p.63Asp [c.187G] mutated protein, and the protein lacking 88 amino acids encoded by exon 2. Overall, these data point to the complex allele HFE c. [187C>G;340+4T>C] being an iron overload genetic predisposition factor.

The c.193T [p.65Cys] mutation, also considered a polymorphism, may, alone or combined with other mutations, be associated with mild iron accumulation [36]. In the present study, the small number of patients carrying the c.193T polymorphism makes it difficult to establish conclusions about the relation of iron overload with this variant. However, genotypic profile analysis revealed that carriers of GP5 CC AT CC GG present a significant risk (RR = 11.44, 95% CI 1.17–112.26, $p = 0.002$; Table 3). In terms of gene expression, these individuals will most likely produce three types of HFE altered proteins: the p.63Asp [c.187G] protein, the p.65Cys [c.193T] protein, and the protein missing exon 2 encoded amino acids.

In summary, we provide evidence that at least the complex allele HFE-c.[187C>G;340+4T>C] has a role, as a genetic predisposition factor, on iron overload in the São Miguel population (Azores, Portugal). Independent replication studies in other populations are needed to confirm this association. Additionally, the HFE-c.845A [p.282Tyr] mutation has a diverse HLA genetic background, since it is associated with six haplotypes, three of them described here for the first time—A*02-B*55, A*24-B*15 and A*03-B*50. These data validate the importance of carrying out epidemiological studies of recessive mutations in relatively small populations like São Miguel Island and are a valuable contribution to a perspective study on iron overload in this population.

**Limitations**

The present work has some limitations, the major one being the small number of patients; however, it includes practically all island’s diagnosed cases of iron overload that meet the
inclusion criteria and is the first report on HFE mutation distribution in the healthy population of São Miguel Island. Nonetheless, replication with a larger sample size is needed in order to validate the results observed here. Another constraint is the lack of functional analysis of the complex allele HFE c.[187C>G;340+4T>C].

Supporting Information

S1 Table. HLA-A-B haplotypes observed in the São Miguel Island general population. (DOCX)

Acknowledgments

We express our acknowledgment to Doctor Graça Porto for her helpful comments on drafting the manuscript. We would like to thank all Head of Departments involved in the clinical evaluation of patients with iron overload, namely Dr. Clara Paiva (Internal Medicine), Dr. Maria Antónia Duarte (Gastroenterology), and Dr. Carlos Pavão (Pneumology). We also acknowledge the Clinical Pathology Department for performing the biochemical analysis. We recognize the help of José Almeida-Mello, from the Azores Genealogical Club, for reconstructing the family’s ascending genealogy. We also thank Justin Scobey and Samuel Zarfos, students from The University of Tennessee at Knoxville and Wheaton College—Norton, respectively, for revising the English language manuscript. Finally, we thank all patients who accepted to participate.

Author Contributions

Conceived and designed the experiments: LMV CCB. Performed the experiments: CCB CTG LF SB MJB TP RC. Analyzed the data: CCB LMV. Contributed reagents/materials/analysis tools: LMV ACR CF AGM GB PM. Wrote the paper: CCB LMV.

References

1. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010; 139: 393–408. doi:10.1053/j.gastro.2010.06.013 PMID: 20542038
2. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A Novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996; 13: 399–408. PMID: 8696333
3. Lin A, Yan WH, Xu HH, Zhu M, Zhou MY. Analysis of the HFE gene (C282Y, H63D and S65C) mutations in a general Chinese Han population. Tissue Antigens. 2007; 70: 252–255. PMID: 17661915
4. Martins R, Picanço I, Nunes B, Romão L, Faustino P. HFE gene mutations are extremely rare in Western sub-Saharan Africa. Ann Hematol. 2005; 84: 686–688. PMID: 15834568
5. Beutler E, Gelbart T. HLA-H mutations in the Ashkenazi Jewish population. Blood Cells Mol Dis. 1997; 23: 95–98. PMID: 9215754
6. Porto G, de Sousa M. Variation in hemochromatosis prevalence and genotype in national groups In: Hemochromatosis Genetics, Pathophysiology, Diagnosis, and Treatment, chapter 5 (eds Barton JC, Edwards CQ), Cambridge University Press, Cambridge, 2000; pp 51–62.
7. Henz S, Reichen J, Liechti-Gallati S. HLA-H gene mutations and haemochromotosis: the likely association of H63D with mild phenotype and the detection of S65C, a novel variant in exon 2. J Hepatol. 1997; 26 (Suppl): 57.
8. Mura C, Raguenes O, Férec C. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood. 1999; 93: 2502–2505. PMID: 10194428
9. Wallace DF, Walker AP, Pietrangelo A, Clare M, Bornford AB, Dixon JL, et al. Frequency of the S65C mutation of HFE and iron overload in 309 subjects heterozygous for C282Y. J Hepatol. 2002; 36: 474–479.
10. Ka C, Le Gac G, Dupradeau FY, Rochette J, Ferec C. The Q283P amino-acid change in HFE leads to structural and functional consequences similar to those described for the mutated 282Y HFE protein. Hum Genet. 2005; 16: 476–475.

11. Floreani A, Navaglia F, Basso D, Zambon CF, Basso G, Germano G, et al. Intron 2 (IVS2, T-C +4) HFE gene mutation associated with S65C causes alternative RNA splicing and is responsible for iron overload. Hepatol Res. 2005; 33: 57–60. PMID: 16099205

12. de Villiers JN, Hillermann R, Loubser L, Kotze MJ. Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria. Hum Mol Genet. 1999; 8: 1517–1522. PMID: 10401000

13. Steiner M, Ocran K, Genschel J, Meier P, Gerl H, Ventz M, et al. A homozygous HFE gene splice site mutation (IVS5+1 G/A) in a hereditary hemochromatosis patient of Vietnamese origin. Gastroenterology. 2002; 122: 789–795. PMID: 11875012

14. Martins R, Silva B, Proença D, Faustino P. Differential HFE gene expression is regulated by alternative splicing in human tissues. PLoS One. 2011; 6: e17542. doi: 10.1371/journal.pone.0017542 PMID: 21407826

15. Salter-Cid L, Brunmark A, Li Y, Leturcq D, Peterson PA, Jackson MR, et al. Transferrin receptor is negatively modulated by the hemochromatosis protein HFE: implications for cellular iron homeostasis. Proc Natl Acad Sci USA. 1999; 96: 5434–5439. PMID: 10318901

16. Cukjati M, Vaupotic T, Rupreht R, Ćurin-Šerbac V. Prevalence of H63D, S65C and C282Y hereditary hemochromatosis gene mutations in Slovenian population by an improved high-throughput genotyping assay. BMC Med Genet. 2007; 8: 69–77. PMID: 18036208

17. Pacheco PR, Branco CC, Gomes CT, Cabral R, Mota-Vieira L. HLA Class I and II profiles in São Miguel Island (Azores): genetic diversity and linkage disequilibrium. BMC Res Notes. 2010; 3: 134–139. doi: 10.1186/1756-0500-3-134 PMID: 20462405

18. Mota-Vieira L, Macedo P, Paiva C, Serpa L, Brandao H, Almeida-Mello J, et al. Pseudodominant transmission of hereditary hemochromatosis in a family from a small geographic area: genealogical and genetic analysis. Am J Hum Genet. 2000; 67 (Suppl1): A1212.

19. Pacheco PR, Branco CC, Cabral R, Costa S, Araújo AL, Peixoto BR, et al. The Y-chromosomal heritage of the Azores Islands population. Am Hum Genet. 2005; 69: 145–156. PMID: 15720296

20. Spínola H, Brehm A, Bettencourt B, Middleton D, Bruges-Armas J. HLA class I and II polymorphisms in Azores show different settlements in Oriental and Central islands. Tissue Antigens. 2005; 66: 217–230. PMID: 16101833

21. Branco CC, Palla R, Lino S, Pacheco PR, Cabral R, De Fez L, et al. Assessment of Azorean ancestry by Alu insertion polymorphisms. Am J Hum Biol. 2006; 18: 223–226. PMID: 16493635

22. Branco CC, Bento MS, Gomes CT, Cabral R, Pacheco PR, Mota-Vieira L. Azores Islands: genetic origin, gene flow and diversity pattern. Ann Hum Biol. 2006; 33: 65–74. doi: 10.1080/03014460701793782 PMID: 18274926

23. Branco CC, Cabrol E, São Bento M, Gomes CT, Cabral R, Vicente AM, et al. Evaluation of linkage disequilibrium on the Xq133 region: comparison between the Azores islands and mainland Portugal. Am J Hum Biol. 2008; 20: 364–366. doi: 10.1002/ajhb.20734 PMID: 18257075

24. Branco CC, Pacheco PR, Cabral R, Vicente AM, Mota-Vieira L. Genetic signature of the São Miguel Island population (Azores) assessed by 21 microsatellite loci. Am J Hum Biol. 2008; 20: 118–120. PMID: 17990326

25. Branco CC, Pacheco PR, Cabrol E, Cabral R, Vicente AM, Mota-Vieira L. Linkage disequilibrium and diversity for three genomic regions in Azoreans and mainland Portuguese. Genet Mol Biol. 2009; 32: 220–226. doi: 10.1590/S1415-47572009000200003 PMID: 21637671

26. Pedersen P, Melsø GV, Milman N. Frequencies of the haemochromatosis gene (HFE) variants C282Y, H63D and S65C in 6,020 ethnic Danish men. Ann Hum Genet. 2002; 66: 157–161. doi: 10.1080/03014460110076018 PMID: 12770794

27. Couto AR, Peixoto MJ, Garrett F, Laranjeira F, Cipriano T, Armas JB. Linkage disequilibrium between S65C HFE mutation and HLA A29-B44 haplotype in Terceira Island, Azores. Hum Immunol. 2003; 64: 625–628. PMID: 12770794

28. Cardoso CS, Oliveira P, Porto G, Oberkanins C, Mascarénhas M, Rodrigues P, et al. Comparative study of the two more frequent HFE mutations (C282Y and H63D): significant different allelic frequencies between the North and South of Portugal. Eur J Hum Genet. 2001; 9: 843–848. PMID: 11781701

29. Yang Y, Férec C, Mora C. SNP and haplotype analysis reveals new HFE variants associated with iron overload trait. Hum Mutat. 2011; 32: 2104–2117.

30. Hoefele J, Nayir A, Chaki M, Imm A, Allen SJ, Otto EA, et al. Pseudodominant inheritance of nephropathesis caused by a homozygous NPHP1 deletion. Pediatr Nephrol. 2011; 26: 967–971. doi: 10.1007/s00467-011-1761-9 PMID: 21258817
31. Cruz E, Vieira J, Almeida S, Lacerda R, Gartner A, Cardoso CS, et al. A study of 82 extended HLA haplotypes in HFE-C282Y homozygous hemochromatosis subjects: relationship to the genetic control of CD8+ T-lymphocyte numbers and severity of iron overload. BMC Med Genet. 2006; 7: 16–27. PMID: 16509978

32. Porto G, Alves H, Rodrigues P, Cabeda JM, Portal C, Ruivo A, et al. Major histocompatibility complex class I associations in iron overload: evidence for a new link between the HFE H63D mutation, HLA-A29, and non-classical forms of hemochromatosis. Immunogenetics. 1998; 47: 404–410. PMID: 9510559

33. Distante S, Robson KJ, Graham-Campbell J, Arnaiz-Villena A, Brissot P, Worwood M. The origin and spread of the HFE-C282Y haemochromatosis mutation. Hum Genet. 2004; 115: 269–279. PMID: 15290237

34. Spínola C, Brehm A, Spínola H. Prevalence of H63D, S65C, and C282Y hereditary hemochromatosis gene variants in Madeira Island (Portugal). Ann Hematol. 2011; 90: 29–32. doi:10.1007/s00277-010-1034-x PMID: 20714725

35. de Diego C, Murga MJ, Martinez-Castro P. Frequency of HFE H63D, S65C and C282Y mutations in patients with iron overload and controls from Toledo, Spain. Genet Test. 2004; 8: 263–267. PMID: 15727249

36. Holmström P, Marmur J, Eggertsen G, Gåshults M, Stål P. Mild iron overload in patients carrying the HFE S65C gene mutation: a retrospective study in patients with suspected iron overload and healthy controls. Gut. 2002; 51: 723–730. PMID: 12377814